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APPLICATION OF TRANSURETHRAL MICROWAVE THERMOTHERAPY
FOR PATIENTS WITH ACUTE URINARY RETENTION AND SEVERE
COMBINED COMORBIDITY FROM BENIGN PROSTATIC HYPERPLASIA
A. Mysak, W. Lamptey
TERNOPIL UNIVERSITY HOSPITAL,
I. YA. HORBACHEVSKY TERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
Background. The incidence of benign prostatic hyperplasia (BPH)  has grown by almost 35 % over the last
five years with an incidence rate of 4438.2 per 100 000 of the respective population (147 677 total patients)  in
Ukrainian men beyond working age in 2007 [3].
Objective. The aim of the study was to assess the efficacy of TUMT in men where BPH was complicated
by AUR and severe comorbidities.
Method. TUMT was performed using the domestically produced equipment ‘ALMGP-01’ at the frequency
of 1300 Hz, rectal temperature of 42.5 °C, and urethral temperature of 44.5 °C. The average session duration
is 46-55 minutes.
Results and Discussion. Subjective self-assessment: no effect of the procedure was detected (urination
not restored) in 9 patients (11.11 %); poor current status with prior temporary improvement (6-9 months of
independent urination with repeated AUR) in 14 patients (17.28 %); satisfactory current status with occasional
dysuric episodes (however better than pre-TUMT status) in 40 patients (49.38 %). Eight patients (22.22 %)
have assessed their status as ‘good’ and ‘excellent’; one patient noted substantial improvement compared to
pre-procedure status. The nine patients with lack of success of restoring physiological urination had the following
peculiarities: intra-vesical growth of BPH and prostatic volume over 85 cm3 in majority of these patients.
Conclusions. Taking into consideration the minimally invasive nature, favourable tolerability and absence
of adverse effects, TUMT can be considered as a method of choice in patients with BPH-triggered AUR and
contraindications to major surgical treatments and general anaesthesia. Remote outcomes of TUMT may be
evaluated as satisfactory, with good effects in 71.62 % patients. However, in prostatic volumes exceeding 85
cm3 and pronounced intravesical pattern of BPH growth the efficacy of TUMT is arguable.
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Introduction
Benign prostatic hyperplasia is a very common
condition, found in middle-aged, senior and elderly
males, according to epidemiological studies [1]. As
for the age, the incidence of this disease is up to
85 % [2]. The incidence of benign prostatic hyper-
plasia (BPH) has grown by almost 35 % over the
last five years which is 4438,2 per 100000 of the
respective population (147 677 patients) in 2007 in
Ukrainian men beyond working age [3].
The pain- and stress-free urination is known to
be an essential component of optimal quality of life.
However, there are moments when the perception
of the quality of life undergoes a radical change. One
of such moments is acute urinary retention (AUR).
Occasionally, acute urinary retention occurs due to
certain triggering factors, such a surgery under
general anaesthesia, excessive fluid intake and
medications with sympathomimetic or anticholinergic
action [4]. However, the main or principal group
consists of over 90% males in whom AUR is a result
of natural development of benign prostatic hyper-
plasia (BPH) [5, 6].
European urological community identified the
following risk factors of AUR: age >70 years, prostatic
volume >30 cm3, uroflowmetric results <12 mL/sec,
IPSS score >7 points, residual urine >50 mL and
PSA levels >1.5 ng/mL [7, 8].
It is generally accepted that the principal methods
of AUR relief in patients with BPH are short-term
bladder catheterisation, trocar-assisted or supra-
pubicepicystostomy, transurethral resection or open
prostatectomy. However, there are situations when
despite a disappointing effect of medical mana-
gement, it is difficult to decide in favour of radical
elimination of AUR due to severe comorbidities. Then
the physician faces a difficult question how to solve
this problem and which treatment modality is best to
spare hold the patient harmless and restore
spontaneous micturition.
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Throughout the last decades, there has been a
search for new therapeutic approaches in sympto-
matic BPH [9]. For a technique to be recognized as
effective it is essential for it to be less invasive and
nevertheless effective, to require no general anaes-
thesia, to have an outpatient option and to have as
few complications as possible. One of the urological
technology achievements to meet the above criteria
is transurethral microwave thermotherapy (TUMT).
The aim of the study was to assess the efficacy
of TUMT in men where BPH was complicated by
AUR and severe comorbidities.
Methods
The Ternopil University Hospital has purchased
and is currently using (since 2002) a local microwave
prostatic hyperthermia device (ALMGP-01), manu-
factured by the JSC RADMIR State Enterprise
Company NDIRV (Kharkov). 516 TUMT procedures
have been performed in BPH patients with high
surgical risk at the Urology Department between
years of 2002 and 2013.
Clinical analysis was performed in medical
records of 81 (15.69 %) patients with AUR-com-
plicated BPH.
Patient complaints were assessed using the
IPSS symptom scale, developed by the American
Urological Association, including the quality of life
question in dysuric patients (QOL).The volume of
the urinary bladder, the thickness of its walls,
prostatic size and volume, as well as residual urine
were assessed with transabdominal ultrasound.
Upper urinary tract function was assessed using
radiological and radionuclide method; the levels of
prostate specific antigen (PSA) in all patients were
within normal limits (up to 4 ng/mL).
Radical surgical techniques for BPH could not
be used due to severe concurrent comorbities in the
patients. In the given investigation, twenty-nine
patients were diagnosed with coronary artery
disease (CAD), diffuse and post-MI cardiosclerosis
and Class IIa-IIb heart failure; 34 patients had CAD
with complicated arrhythmias; 13 patients had
residual post-CVA findings; 32 patients had Stage
III hypertension; 17 patients had chronic bronchitis,
emphysema and Stage II respiratory failure; 8
patients had severe Type 2 diabetes; 21 patients
had varicose leg veins with Stage II–III chronic
venous failure; 9 patients had Stage II chronic kidney
disease; 2 patients had ankylosing spondylitis
(Bechterew’s disease) and 3 patients had bilateral
coxarthrosis. Each of the TUMT patients had three
to five concurrent comorbidities.
TUMT was performed using equipment
‘ALMGP-01’ (Kharkov, Ukraine) at the frequency of
1300 Hz, rectal temperature of 42.5 °C and urethral
temperature of 44.5 °C. The average session
duration was 46-55 minutes. According to ultrasound
examination, the prostatic volume was within the
range of 46 cm3 to 102 cm3, with a size of 74.5 cm3
on average. The patients had a Foley catheter
inserted repeatedly and were administered oral
antibacterial drugs, usually fluoroquinolones or
cephalosporins after completion of the TUMT
session. Postoperative hospital stay was 4 to 7 days,
4.92 days on the average. Three days prior to urethral
catheter removal, 1a-adrenoblocker tamsulosin
(Omnic 0.4 mg/day) was used. The catheter was
removed on Week 4 post-TUMT, after completed
resorption of cellular necrosis.
Results
Most patients tolerated the TUMT session
favourably. Only 5 patients (6.17 %) had a short-
term urethrorrhagia; 2 patients (2.46 %) had an acute
pyelonephritis and 2 patients (2.46 %) had a single
day urethral fever in post operative period. The
patients had the following baseline preoperative
findings: IPSS 21.62±1.14 and QoL: 4.42±0.36. The
following results were obtained in analysis of these
findings 9–12 months post-TUMT: the IPSS score
decreased to 18.42±1.63 and the quality of life index
(QoL) decreased to 3.07±0.24. Physiological
urination was restored in 72 patients (88.89 %) after
removal of the Foley catheter. Residual urine in the
patients where urination was restored was between
15 and 145 mL, 48.25±18.36 mL on the average.
PSA levels were subsequently within normal limits.
Discussion
Subjective self-assessment of TUMT efficacy by
the AUR patients was the following: no effect of the
procedure was detected (urination not restored) in 9
patients (11.11 %); poor current status with prior
temporary improvement (6–9 months of independent
urination with repeated AUR) in 14 patients
(17.28 %); satisfactory current status with occasional
dysuric episodes (however better than pre-TUMT
status) in 40 patients (49.38 %). Eight patients
(22.22 %) have assessed their status as ‘good’ and
‘excellent’; one patient note substantial improvement
compared to pre-procedure status. The nine patients
with lack of success restoring physiological urination
had the following peculiarities: intra-vesical growth
of BPH and prostatic volume over 85 cm3 in majority
of these patients.
Within a year’s span, post-TUMT surgical
treatment was undertaken in 8 patients with lack of
independent urination (2 patients had transvesical
prostatectomy, 4 patients had TURP and 2 more
patients had suprapubic cystostomy placed). One
patient refused surgical treatment and was on an
indwelling catheter for 3 years already. Concerning
the temporary improvement population, 11 patients
A. Mysak et al.
29
S
U
R
G
IC
A
L
D
IS
E
A
S
E
S
IJMMR 2015 Vol. 1 No. 1
had surgeries (4 patients had transvesical pros-
tatectomy, 6 patients had TURP and 1 more patient
had suprapubic trocar cystostomy placed). Three
patients of this group had repeated TUM session
after recurrent AUR with independent urination
successfully restored. It is noteworthy that open post-
TUMT prostatectomies were associated with difficulty
enucleating hyperplastic nodules due to proliferative
changes in the nodes and the adjacent tissues.
Another peculiar observation was that post-TUMT
open prostatectomies, as well as post-TUMT TURP
procedures, were associated with less pronounced
and storter haemorrhage.
Conclusions
Taking into consideration the minimally invasive
nature, favourable tolerability and absence of
adverse effects, TUMT can be considered a method
of choice in patients with BPH-triggered AUR and
contraindications to major surgical treatments and
general anaesthesia. Remote outcomes of TUMT
may be evaluated as satisfactory, with good effects
in 71.62 % patients. However, the efficacy of TUMT
is arguable in prostatic volumes exceeding 85 cm3
and pronounced intravesical pattern of BPH growth.
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